Abstract
Realization of part of clinical trial called: Randomized, double-blind, controlled clinical phase III trial to determine the safety and efficacy of intravitreal product applied FovistaTM (anti-PDGF-B pegylated aptamer) given in combination with Lucentis (R) compared with Lucentis (R) monotherapy in patients subfovální with neovascular age-related macular degeneration